Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02773030 · OUTCOME

Time to Response (TTR)

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma · Source last updated 2026-03-20

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
Full Range
Time frame
On Average of (Cohort A:19.14, Cohort B: 12.39, Cohort D: 7.54, Cohort E: 5.44, Cohort F: 4.97, Cohort G: 12.30, Cohort H: 4.14, Cohort I: 8.79, Cohort J: 4.76, Cohort K: 6.51) Weeks

What was measured

Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.

Analysis population: Safety Population - Responders Only

Groups in this outcome

Cohort A: Treatment 1

CC220 0.30mg

Cohort A: Treatment 2

CC220 0.45mg

Cohort A: Treatment 3

CC220 0.60mg

Cohort A: Treatment 4

CC220 0.75mg

Cohort A: Treatment 5

CC220 0.90mg

Cohort A: Treatment 6

CC220 1.0mg

Cohort B: Treatment 1

CC220 0.30mg + DEX

Cohort B: Treatment 2

CC220 0.45mg + DEX

Cohort B: Treatment 3

CC220 0.60mg + DEX

Cohort B: Treatment 4

CC220 0.75mg + DEX

Cohort B: Treatment 5

CC220 0.90mg + DEX

Cohort B: Treatment 6

CC220 1.0mg + DEX

Cohort B: Treatment 7

CC220 1.1mg + DEX

Cohort B: Treatment 8

CC220 1.2mg + DEX

Cohort B: Treatment 9

CC220 1.3.mg + DEX

Cohort B: Treatment 10

CC220 1.6mg + DEX

Cohort D: Treatment 1

CC220 + DEX

Cohort E: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort E: Treatment 2

CC220 1.1mg + DARA + DEX

Cohort E: Treatment 3

CC220 1.2mg + DARA + DEX

Cohort E: Treatment 4

CC220 1.3mg + DARA + DEX

Cohort E: Treatment 5

CC220 1.6mg + DARA + DEX

Cohort F: Treatment 1

CC220 1.0mg + BORT + DEX

Cohort F: Treatment 2

CC220 1.1mg + BORT + DEX

Cohort F: Treatment 3

CC220 1.3mg + BORT + DEX

Cohort F: Treatment 4

CC220 1.6mg + BORT + DEX

Cohort G: Treatment 1

CC220 1.1mg + CFZ + DEX

Cohort G: Treatment 2

CC220 1.3mg + CFZ + DEX

Cohort G: Treatment 3

CC220 1.6mg + CFZ + DEX

Cohort H1

CC220 + DEX

Cohort H2

CC220 + DEX

Cohort I

CC220 + DEX

Cohort J1: Treatment 1

CC220Vd 1.0mg + NE-ASCT

Cohort J1: Treatment 2

CC220Vd 1.6mg + NE-ASCT

Cohort K: Treatment 1

CC220 1.0mg + DARA + DEX

Cohort K: Treatment 2

CC220 1.3mg + DARA + DEX

Cohort K: Treatment 3

CC220 1.6mg + DARA + DEX

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort A: Treatment 10
Cohort A: Treatment 20
Cohort A: Treatment 30
Cohort A: Treatment 42
Cohort A: Treatment 50
Cohort A: Treatment 61
Cohort B: Treatment 13
Cohort B: Treatment 21
Cohort B: Treatment 31
Cohort B: Treatment 42
Cohort B: Treatment 54
Cohort B: Treatment 63
Cohort B: Treatment 72
Cohort B: Treatment 82
Cohort B: Treatment 97
Cohort B: Treatment 104
Cohort D: Treatment 128
Cohort E: Treatment 10
Cohort E: Treatment 21
Cohort E: Treatment 31
Cohort E: Treatment 48
Cohort E: Treatment 514
Cohort F: Treatment 11
Cohort F: Treatment 23
Cohort F: Treatment 37
Cohort F: Treatment 46
Cohort G: Treatment 13
Cohort G: Treatment 24
Cohort G: Treatment 33
Cohort H14
Cohort H21
Cohort I14
Cohort J1: Treatment 11
Cohort J1: Treatment 215
Cohort K: Treatment 124
Cohort K: Treatment 225
Cohort K: Treatment 322

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Cohort A: Treatment 424.64Not reported8.141.1Not reported
Cohort A: Treatment 68.14Not reported8.148.14Not reported
Cohort B: Treatment 17.86Not reported5.78.1Not reported
Cohort B: Treatment 256.0Not reported56.056.0Not reported
Cohort B: Treatment 38.14Not reported8.148.14Not reported
Cohort B: Treatment 433.14Not reported10.156.1Not reported
Cohort B: Treatment 54.14Not reported4.18.3Not reported
Cohort B: Treatment 67.14Not reported4.116.1Not reported
Cohort B: Treatment 712.14Not reported4.120.1Not reported
Cohort B: Treatment 810.21Not reported8.412.0Not reported
Cohort B: Treatment 98.14Not reported4.120.4Not reported
Cohort B: Treatment 108.07Not reported4.312.1Not reported
Cohort D: Treatment 14.21Not reported3.919.9Not reported
Cohort E: Treatment 24.14Not reported4.144.14Not reported
Cohort E: Treatment 37.86Not reported7.867.86Not reported
Cohort E: Treatment 44.14Not reported4.112.0Not reported
Cohort E: Treatment 54.14Not reported4.013.1Not reported
Cohort F: Treatment 16.14Not reported6.146.14Not reported
Cohort F: Treatment 23.14Not reported3.113.1Not reported
Cohort F: Treatment 33.71Not reported3.19.1Not reported
Cohort F: Treatment 43.36Not reported3.07.3Not reported
Cohort G: Treatment 14.14Not reported4.18.1Not reported
Cohort G: Treatment 28.14Not reported4.062.1Not reported
Cohort G: Treatment 38.86Not reported4.111.1Not reported
Cohort H16.14Not reported4.18.3Not reported
Cohort H24.14Not reported4.144.14Not reported
Cohort I6.29Not reported4.123.3Not reported
Cohort J1: Treatment 13.14Not reported3.143.14Not reported
Cohort J1: Treatment 23.14Not reported3.017.0Not reported
Cohort K: Treatment 15.07Not reported4.049.0Not reported
Cohort K: Treatment 24.14Not reported4.025.1Not reported
Cohort K: Treatment 34.14Not reported4.09.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG003
        lower Limit
        8.1
        upper Limit
        41.1
        value
        24.64
      2. group Id
        OG005
        lower Limit
        8.14
        upper Limit
        8.14
        value
        8.14
      3. group Id
        OG006
        lower Limit
        5.7
        upper Limit
        8.1
        value
        7.86
      4. group Id
        OG007
        lower Limit
        56.0
        upper Limit
        56.0
        value
        56.0
      5. group Id
        OG008
        lower Limit
        8.14
        upper Limit
        8.14
        value
        8.14
      6. group Id
        OG009
        lower Limit
        10.1
        upper Limit
        56.1
        value
        33.14
      7. group Id
        OG010
        lower Limit
        4.1
        upper Limit
        8.3
        value
        4.14
      8. group Id
        OG011
        lower Limit
        4.1
        upper Limit
        16.1
        value
        7.14
      9. group Id
        OG012
        lower Limit
        4.1
        upper Limit
        20.1
        value
        12.14
      10. group Id
        OG013
        lower Limit
        8.4
        upper Limit
        12.0
        value
        10.21
      11. group Id
        OG014
        lower Limit
        4.1
        upper Limit
        20.4
        value
        8.14
      12. group Id
        OG015
        lower Limit
        4.3
        upper Limit
        12.1
        value
        8.07
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    3. group Id
      OG002
      value
      0
    4. group Id
      OG003
      value
      2
    5. group Id
      OG004
      value
      0
    6. group Id
      OG005
      value
      1
    7. group Id
      OG006
      value
      3
    8. group Id
      OG007
      value
      1
    9. group Id
      OG008
      value
      1
    10. group Id
      OG009
      value
      2
    11. group Id
      OG010
      value
      4
    12. group Id
      OG011
      value
      3
    units
    Participants
description
Time to response is defined as the time from the first dose date of study treatment to the first date of documented response (PR or better). Time to response will be summarized for responders using descriptive statistics by cohort and dose level.
dispersion Type
Full Range
groups
  1. description
    CC220 0.30mg
    id
    OG000
    title
    Cohort A: Treatment 1
  2. description
    CC220 0.45mg
    id
    OG001
    title
    Cohort A: Treatment 2
  3. description
    CC220 0.60mg
    id
    OG002
    title
    Cohort A: Treatment 3
  4. description
    CC220 0.75mg
    id
    OG003
    title
    Cohort A: Treatment 4
  5. description
    CC220 0.90mg
    id
    OG004
    title
    Cohort A: Treatment 5
  6. description
    CC220 1.0mg
    id
    OG005
    title
    Cohort A: Treatment 6
  7. description
    CC220 0.30mg + DEX
    id
    OG006
    title
    Cohort B: Treatment 1
  8. description
    CC220 0.45mg + DEX
    id
    OG007
    title
    Cohort B: Treatment 2
  9. description
    CC220 0.60mg + DEX
    id
    OG008
    title
    Cohort B: Treatment 3
  10. description
    CC220 0.75mg + DEX
    id
    OG009
    title
    Cohort B: Treatment 4
  11. description
    CC220 0.90mg + DEX
    id
    OG010
    title
    Cohort B: Treatment 5
  12. description
    CC220 1.0mg + DEX
    id
    OG011
    title
    Cohort B: Treatment 6
param Type
MEDIAN
population Description
Safety Population - Responders Only
reporting Status
POSTED
time Frame
On Average of (Cohort A:19.14, Cohort B: 12.39, Cohort D: 7.54, Cohort E: 5.44, Cohort F: 4.97, Cohort G: 12.30, Cohort H: 4.14, Cohort I: 8.79, Cohort J: 4.76, Cohort K: 6.51) Weeks
title
Time to Response (TTR)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice